Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Single Arm Trial of Immunotherapy With Autologous Antigen Presenting Cells Loaded With PA2024 [sipuleucel-T] (APC8015F) for Subjects With Objective Disease Progression and Disease-Related Pain on Protocol D9902 Part B.

Trial Profile

An Open Label, Single Arm Trial of Immunotherapy With Autologous Antigen Presenting Cells Loaded With PA2024 [sipuleucel-T] (APC8015F) for Subjects With Objective Disease Progression and Disease-Related Pain on Protocol D9902 Part B.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2013

At a glance

  • Drugs Sipuleucel-T (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 31 Jan 2012 Results presented at the 2012 Genitourinary Cancers Symposium, according to a Dendreon Corporation media release.
    • 17 Feb 2011 Results presented at the 2011 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top